<DOC>
	<DOC>NCT00225199</DOC>
	<brief_summary>The purpose of this study is to demonstrate safety and efficacy of SH T00660AA compared to placebo in the treatment of endometriosis</brief_summary>
	<brief_title>Efficacy and Safety of SH T00660AA in Treatment of Endometriosis</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Female patients with endometriosisassociated pelvic pain Pregnant or lactating women history or suspicion of hormone dependent tumor therapy resistant endometriosis need for primary surgical treatment any other conditions which forbid the participation.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>